

## Biomarkers Congress 2020 scheduled during June 15-16, 2020 at Dubai, UAE

**Yousef Salama**

An-Najah National University, Palestine, E-mail: yousefsalama123@gmail.com

### 2020 Conference Announcement

**Biomarkers** are molecules that signify an irregular process in your body and may be a sign of underlying disease or illness. Biomarkers are useful in various ways, including assessing disease progression, determining the most appropriate treatment protocols for a specific type of cancer, and detecting long-term vulnerability to or recurrence of cancer.

**Biomarker Congress 2019** is an event that aims to explore the innovative approaches for biomarkers, clinical research, cancer medicine and innovations in biomarkers scheduled to be held during June 15-16, 2020 at Abu Dhabi, UAE. The event was held to provide great scope for interaction of professionals working in the field of Biomarkers, **Immunotherapy**, Cancer Therapy, Breast cancer, Oncology & Neurological biomarkers on a single platform.

The **biomarker** market presents the highest of all prospects in sub-segments of representative diseases. This study examines one of the most important engines of the market: the overview of **combination analyses**, which are estimated to continue contributing significantly to market development during the forecast period. This report studies **emerging markets** by disease segment. Endless growth is estimated in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia. This report seeks to address issues of critical importance to analyze a changing market dynamics, emerging players and machinery, approaches to access emerging markets and specific **disease segments** and geographies to allocate resources and make operative decisions. For companies with an actual approach, the market opportunity expects you. It is important to emphasize that the ability to develop an effective strategy begins with the place where the opportunity exists and ends with the way to execute effectively to obtain the opportunity's profits.

- from National University, Singapore presented a session talk entitled Companion diagnostics for Trastuzumab based neoadjuvant therapy: Two is better than one.
- from An-Najah National University, Palestine presented a session talk entitled Fibrinolytic factors promote inflammatory colonic carcinogenesis through miR-126-mediated targeting of the proteolytic niche.

ME Conferences is glad to schedule the **"2nd International Conference on Biomarkers and Clinical Research"** during **June 15-16, 2020 at Dubai, UAE**.

Meet the future as it pledge to **Biomarkers and Clinical Research** by bringing the worldwide, Oncologists, Biomarker Researches, Cardiologists, Radiologists, Clinical Researchers, Scientists, Scholars and Specialists to Dubai, UAE.

### References:

1. Companion diagnostics for Trastuzumab based neoadjuvant therapy by Lim Yoon Pin from National University, Singapore.
2. Identification of potential early biomarkers of aortopathy by Salah A Mohamed from University of Luebeck, Germany.

Link:- [https://www.conferenceseries.com/Past\\_Reports/biomarkers-congress-2019-gallery](https://www.conferenceseries.com/Past_Reports/biomarkers-congress-2019-gallery)

### Sarah Williams

Program Manager | Biomarkers Congress 2020

Send a mail to [biomarkers@memeetings.com](mailto:biomarkers@memeetings.com)

Phone No.: +1-201-380-5561 | Ext. No.: 7007

WhatsApp No: +44-144-360-6408